Show simple item record

dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorDafni, U.en
dc.contributor.authorBafaloukos, Dimitriosen
dc.contributor.authorSkarlos, Dimosthenis V.en
dc.contributor.authorMoulopoulos, L. A.en
dc.contributor.authorRazi, E. D.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorAravantinos, Gerasimosen
dc.contributor.authorBriassoulis, E. Chen
dc.contributor.authorPapakostas, P.en
dc.contributor.authorAbela, K.en
dc.contributor.authorGogas, H.en
dc.contributor.authorKosmidis, Paraskevas A.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorDimopoulos, M. A.en
dc.creatorFountzilas, Georgeen
dc.creatorPapadimitriou, C.en
dc.creatorDafni, U.en
dc.creatorBafaloukos, Dimitriosen
dc.creatorSkarlos, Dimosthenis V.en
dc.creatorMoulopoulos, L. A.en
dc.creatorRazi, E. D.en
dc.creatorKalofonos, H. P.en
dc.creatorAravantinos, Gerasimosen
dc.creatorBriassoulis, E. Chen
dc.creatorPapakostas, P.en
dc.creatorAbela, K.en
dc.creatorGogas, H.en
dc.creatorKosmidis, Paraskevas A.en
dc.creatorPavlidis, Nicholasen
dc.creatorDimopoulos, M. A.en
dc.date.accessioned2018-06-22T09:53:06Z
dc.date.available2018-06-22T09:53:06Z
dc.date.issued2001
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41658
dc.description.abstractPurpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, 183 eligible patients with ABC entered the study. Chemotherapy in group A (93 patients) consisted of four cycles of epirubicin at a dose of 110 mg/m2 followed by four cycles of paclitaxel at a dose of 225 mg/m2 in a 3-hour infusion. All cycles were repeated every 2 weeks with granulocyte colony-stimulating factor support. The therapeutic regimen in group B (90 patients) consisted of epirubicin (80 mg/m2) immediately followed by paclitaxel (175 mg/m2 in a 3-hour infusion) every 3 weeks for six cycles. Results: In total, 79 patients (85%) in group A and 72 patients (80%) in group B completed treatment. The median relative dose-intensity of epirubicin was 0.96 in both groups, and that of paclitaxel was 0.96 and 0.97 in groups A and B, respectively. The complete response rate was higher in group A (21.5% v 9% P = .02). Nevertheless, there was no significant difference in the overall response rate between the two groups (55% v 42%, P = .10). Severe neutropenia was more frequently observed with concurrent treatment. After a median follow-up of 16.5 months, median time to progression was 10 months in group A and 8.5 months in group B (P = .27), and median survival was 21.5 and 20 months, respectively (P = .17). Conclusion: The present study failed to demonstrate a significant difference in overall response rate between dose-dense sequential administration of epirubicin and paclitaxel compared with the combination of the two drugs given on the same day, even though the sequential treatment resulted in a significantly higher complete response rate. © 2001 by American Society of Clinical Oncology.en
dc.language.isoengen
dc.sourceJournal of Clinical Oncologyen
dc.subjectArticleen
dc.subjectMaleen
dc.subjectHumanen
dc.subjectAgeden
dc.subjectHumansen
dc.subjectAdulten
dc.subjectBreast canceren
dc.subjectBreast neoplasmsen
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectAdvanced canceren
dc.subjectCancer combination chemotherapyen
dc.subjectCancer survivalen
dc.subjectDisease progressionen
dc.subjectFollow upen
dc.subjectPaclitaxelen
dc.subjectPriority journalen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectClinical trialen
dc.subjectControlled clinical trialen
dc.subjectDrug efficacyen
dc.subjectGranulocyte colony-stimulating factoren
dc.subjectNeutropeniaen
dc.subjectRecombinant granulocyte colony stimulating factoren
dc.subjectTreatment outcomeen
dc.subjectSurvival analysisen
dc.subjectDrug administration scheduleen
dc.subjectRandomized controlled trialen
dc.subjectDose-response relationshipen
dc.subjectDrugen
dc.subjectEpirubicinen
dc.subjectDose time effect relationen
dc.titleDose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology groupen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1200/JCO.2001.19.8.2232
dc.description.volume19
dc.description.issue8
dc.description.startingpage2232
dc.description.endingpage2239
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record